ABIVAX Société Anonyme (ABVX.PA)
EUR 7.48
(2.89%)
EUR 7.48
(2.89%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -147.74 Million EUR | -111.52% |
| 2022 | -69.84 Million EUR | -68.89% |
| 2021 | -41.35 Million EUR | -10.14% |
| 2020 | -37.55 Million EUR | -22.58% |
| 2019 | -30.63 Million EUR | -93.6% |
| 2018 | -15.82 Million EUR | -41.0% |
| 2017 | -11.22 Million EUR | 21.57% |
| 2016 | -14.3 Million EUR | 10.32% |
| 2015 | -15.95 Million EUR | -96.99% |
| 2014 | -8.09 Million EUR | -37.43% |
| 2013 | -5.89 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -81.63 Million EUR | 0.0% |
| 2023 Q2 | -51.95 Million EUR | 0.0% |
| 2023 FY | -147.74 Million EUR | -111.52% |
| 2023 Q4 | -95.78 Million EUR | 0.0% |
| 2022 Q2 | -29.55 Million EUR | 0.0% |
| 2022 Q4 | -40.29 Million EUR | 0.0% |
| 2022 FY | -69.84 Million EUR | -68.89% |
| 2021 FY | -41.35 Million EUR | -10.14% |
| 2021 Q2 | -16.53 Million EUR | 0.0% |
| 2021 Q4 | -24.82 Million EUR | 0.0% |
| 2020 Q2 | -15.42 Million EUR | 0.0% |
| 2020 Q4 | -22.12 Million EUR | 0.0% |
| 2020 FY | -37.55 Million EUR | -22.58% |
| 2019 Q2 | -14.17 Million EUR | 0.0% |
| 2019 FY | -30.63 Million EUR | -93.6% |
| 2019 Q4 | -16.46 Million EUR | 0.0% |
| 2018 FY | -15.82 Million EUR | -41.0% |
| 2018 Q4 | -8.57 Million EUR | 0.0% |
| 2018 Q2 | -7.24 Million EUR | 0.0% |
| 2017 FY | -11.22 Million EUR | 21.57% |
| 2017 Q4 | -5.67 Million EUR | 0.0% |
| 2017 Q2 | -5.54 Million EUR | 0.0% |
| 2016 FY | -14.3 Million EUR | 10.32% |
| 2016 Q2 | -8.27 Million EUR | 0.0% |
| 2016 Q4 | -6.03 Million EUR | 0.0% |
| 2015 Q2 | -7.17 Million EUR | 0.0% |
| 2015 FY | -15.95 Million EUR | -96.99% |
| 2015 Q4 | -8.78 Million EUR | 0.0% |
| 2014 Q4 | -4.42 Million EUR | -199900.0% |
| 2014 FY | -8.09 Million EUR | -37.43% |
| 2014 Q1 | -326.50 EUR | 0.0% |
| 2014 Q2 | -653 Thousand EUR | -199900.0% |
| 2014 Q3 | -2213.50 EUR | 99.66% |
| 2013 FY | -5.89 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -4099.545% |
| Adocia SA | -21.16 Million EUR | -598.138% |
| Aelis Farma SA | -5.07 Million EUR | -2809.413% |
| Biophytis S.A. | -17.02 Million EUR | -767.732% |
| Advicenne S.A. | -7.03 Million EUR | -2001.266% |
| genOway Société anonyme | 1.56 Million EUR | 9524.748% |
| IntegraGen SA | -171.39 Thousand EUR | -86096.536% |
| Medesis Pharma S.A. | -3.95 Million EUR | -3631.288% |
| Neovacs S.A. | -8.74 Million EUR | -1589.722% |
| NFL Biosciences SA | -3.74 Million EUR | -3844.492% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 186713.447% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -4559.176% |
| Sensorion SA | -22.06 Million EUR | -569.616% |
| Theranexus Société Anonyme | -6.82 Million EUR | -2063.753% |
| TME Pharma N.V. | -6.73 Million EUR | -2093.29% |
| Valbiotis SA | -7.36 Million EUR | -1905.157% |
| TheraVet SA | -1.57 Million EUR | -9305.955% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -626.209% |
| argenx SE | -272.91 Million EUR | 45.866% |
| BioSenic S.A. | -28.77 Million EUR | -413.378% |
| Celyad Oncology SA | -8.44 Million EUR | -1648.816% |
| DBV Technologies S.A. | -67.26 Million EUR | -119.624% |
| Galapagos NV | 211.69 Million EUR | 169.788% |
| Genfit S.A. | -28.89 Million EUR | -411.317% |
| GeNeuro SA | -14.75 Million EUR | -901.152% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -860.598% |
| Innate Pharma S.A. | -7.57 Million EUR | -1851.651% |
| Inventiva S.A. | -110.42 Million EUR | -33.791% |
| MaaT Pharma SA | -19.71 Million EUR | -649.303% |
| MedinCell S.A. | -25.03 Million EUR | -490.063% |
| Nanobiotix S.A. | -39.7 Million EUR | -272.141% |
| Onward Medical N.V. | -36.18 Million EUR | -308.336% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -4306.278% |
| OSE Immunotherapeutics SA | -23 Million EUR | -542.264% |
| Oxurion NV | -18.96 Million EUR | -678.85% |
| Pharming Group N.V. | -9.75 Million EUR | -1414.259% |
| Poxel S.A. | -35.09 Million EUR | -321.032% |
| GenSight Biologics S.A. | -26.22 Million EUR | -463.463% |
| Transgene SA | -22.32 Million EUR | -561.68% |
| Financière de Tubize SA | 88.15 Million EUR | 267.598% |
| UCB SA | 343 Million EUR | 143.073% |
| Valneva SE | -101.42 Million EUR | -45.659% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | -421.276% |